This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bone Metabolism Therapeutics Market To 2018 - Hyperparathyroidism Sector To Decline In The Absence Of New Product Launches And Increased Generic Erosion For Zemplar, Hectorol And Sensipar

5.1.4 Treatment Usage Patterns 36

5.1.5 Treatment Flow Algorithm 38

5.1.6 Drivers and Barriers for the Osteoporosis Therapeutics Market 39

5.2 Paget's Disease of Bone Therapeutics Market 40

5.2.1 Introduction 40

5.2.2 Revenue 40

5.2.3 Annual Cost of Treatment 45

5.2.4 Treatment Usage Patterns 46

5.2.5 Treatment Flow Algorithm 48

5.2.6 Drivers and Barriers for the Paget's Disease of Bone Therapeutics Market 49

5.3 Hyperparathyroidism Therapeutics Market 50

5.3.1 Introduction 50

5.3.2 Revenue 50

5.3.3 Annual Cost of Treatment 55

5.3.4 Treatment Usage Patterns 56

5.3.5 Treatment Flow Algorithm 58

5.3.6 Drivers and Barriers for the Hyperparathyroidism Therapeutics Market 59

5.4 Bone Metastases Therapeutics Market 60

5.4.1 Introduction 60

5.4.2 Revenue 60

5.4.3 Annual Cost of Treatment 65

5.4.4 Treatment Usage Patterns 66

5.4.5 Treatment Flow Algorithm 68

5.4.6 Drivers and Barriers for the Bone Metastases Therapeutics Market 68

6 Bone Metabolism Therapeutics Market to 2018 - Pipeline Analysis 70

6.1 Introduction 70

6.2 Bone Metabolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 72

6.2.1 Filed Molecules 72

6.2.2 Phase III 73

6.2.3 Phase II 78

6.2.4 Phase I 80

6.2.5 Preclinical Phase 81

6.2.6 Discovery Phase 82

6.3 Profiles of Promising Molecules in the Bone Metabolism Therapeutics Market 82

6.3.1 Alpharadin (radium-223 chloride) 82

6.3.2 Orazol (Zoledronic acid) 83

6.3.3 Xgeva (denosumab) 83

6.3.4 Boniva (ibandronate sodium hydrate) 84

6.3.5 Odanacatib (odanacatib) 85

6.3.6 GTH-42V 85

6.3.7 Viviant (bazedoxifene) 86

7 Bone Metabolism Therapeutics Market to 2018 - Competitive Profiling 87

7.1 Competitive Profiling 87

7.1.1 Amgen Inc. 87

7.1.2 Abbott Laboratories 89

7.1.3 Genzyme Corporation 90

7.1.4 Merck & Co., Inc. 91

7.1.5 Novartis AG 93

8 Bone Metabolism Therapeutics Market to 2018 - Strategic Consolidations 95

8.1 Mergers and Acquisitions 95

8.1.1 Segmentation by Deal Value 97

8.1.2 Segmentation by Geography 99

8.2 Co-development Deals 100

4 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs